+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast - 2028

  • ID: 4911966
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 158 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Roche
  • MORE
The ‘Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PF-ILD in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

PF-ILD is a collective term used for indications that share a common progressive phenotype. The phenotype is characterized by worsening respiratory symptoms, lung function decline, limited response to immune-modulatory therapies, decreased quality of life, and potentially, early death. Interstitial lung disease (ILD) encompasses a large group of more than 200 parenchymal pulmonary disorders, of which the majority are classified as rare. ILD is further classifies into various types and subtypes. The major classification includes idiopathic interstitial pneumonia (IIPs), autoimmune ILDs, hypersensitivity pneumonitis (HP), sarcoidosis, and several other ILDs. Further, IIP is classified into idiopathic pulmonary fibrosis (IPF) - which contributes to the majority of the cases - , iNSIP, unclassifiable IIPs, and others IIPs. Autoimmune ILDs are classified into IPAF, RA-ILD, SSc-ILD, and other autoimmune ILDs.

According to this research, the patient pool of PF-ILD includes the cases of IPF, iNSIP, unclassifiable IIPs, IPAF, RA-ILD, SSc-ILD, HP, sarcoidosis and other ILDs related to occupational exposures.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017–2028.

Progressive-Fibrosing Interstitial Lung Disease–Disease Understanding

PF-ILDs is characterized by worsening respiratory symptoms, lung function decline, limited response to immune-modulatory therapies, decreased quality of life, and potentially, early death. Irrespective of the clinical diagnosis, these PF-ILDs show commonalities in the underlying pathogenetic mechanisms that drive a self-sustaining process of pulmonary fibrosis.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, Type-specific Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, Subtype-specific Prevalent Cases of Interstitial Lung Disease (ILD) in the 7MM, and Total Prevalent Cases of PF-ILD in the 7MM) scenario of PF-ILD in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2028.

According to this research, the total prevalent population of Interstitial Lung Disease in seven major markets was 736,184 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2028).

The total prevalent population of PF-ILD in seven major markets was 228,613 in 2017.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Drug Chapters

Evidence-based treatment for PFILDs patients’ are currently limited, and often receive corticosteroids and/or off-label immunosuppressive therapy with a variable outcome. Because of commonalities between IPF and PF-ILDs, it has been proposed that the potential efficacy and tolerability of antifibrotic drugs, like pirfenidone and nintedanib, should be evaluated in PF-ILDs. By far, the most commonly used first-line therapy for all the non-IPF fibrosing ILDs was corticosteroids. Because PF-ILDs have been defined by progression despite conventional therapy, there is inherently a substantial unmet need for the treatment of these conditions. Antifibrotic drugs effective to slow down disease progression in IPF may conceivably have comparable efficacy in other PF-ILDs.

Not many companies are working on this patient pool. Currently, two companies, i.e., Boehringer Ingelheim and Roche are investigating their potential molecules to provide treatment of PF-ILD. Nintedanib (Ofev) and Pirfenidone (Esbriet) is under development for PF-ILD. Both the drugs are approved for IPF and are being tested to know whether they can be a potential approach for PF-ILD. Pirfenidone is under development for SSc-ILD as well, but recently, it was reported that it does not stabilize or improve lung function in patients with SSc-ILD. The failure of pirfenidone can be proved a boon for nintedanib, and hence it is expected that nintedanib will generate a major market revenue than pirfenidone.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market Outlook

According to this research, the total market size of PF-ILDs in seven major markets was USD 233.19 million in 2017. The market size of PF-ILD is expected to increase at a significant CAGR during the study period (2017–2028).

Among all the seven major markets, the United States accounts for the highest market size of PF-ILD. In 2017, the market size of PF-ILD was found to be USD 158.73 million.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Drugs Uptake

The current market size of PF-ILD is mainly attributed by corticosteroids, mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, and cyclophosphamide. The market size is expected to increase during the forecast period (2019–2028), due to potential therapies nintedanib (Ofev) and pirfenidone (Esbriet).

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Report Insights
  • Patient Population by total prevalent cases of ILD
  • Type-specific prevalent cases of ILD
  • Subtype-specific prevalent cases of ILD
  • Prevalent cases of PF-ILD
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving PF-ILD market
  • Organize sales and marketing efforts by identifying the best opportunities for PF-ILD market
  • To understand the future market competition in the PF-ILD market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Roche
  • MORE
1. Key Insights

2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market Overview at a Glance
2.1. Market Share (%) Distribution of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in 2017
2.2. Market Share (%) Distribution of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in 2028

3. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD): Disease Background and Overview
3.1. Introduction
3.2. Types of ILDs progressing into Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
3.2.1. Idiopathic Pulmonary Fibrosis (IPF)
3.2.2. Chronic Hypersensitivity Pneumonitis (HP)
3.2.3. Idiopathic Nonspecific Interstitial Pneumonia (INSIP)
3.2.4. Unclassifiable Idiopathic Interstitial Pneumonias (unclassifiable IIPs)
3.2.5. Autoimmune Interstitial Lung Diseases (CTD-ILDs)
3.2.6. Chronic Sarcoidosis
3.2.7. Exposure-related ILDs
3.3. Pathogenesis of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
3.4. Predictors of Disease Progression
3.5. Diagnosis of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
3.6. Diagnostic Algorithm of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Forecast Methodology
4.3. 7MM Total Prevalent Patient Population of Interstitial Lung Disease (ILD)
4.4. 7MM Subtype-specific Prevalence of Interstitial Lung Disease (ILD)
4.5. 7MM Total Prevalent Patient Population of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
4.6. 7MM Total Prevalent Patient Population of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) by subtypes

5. Country Wise-Epidemiology of PF-ILD
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Interstitial Lung Disease (ILD) in the United States
5.1.3. Type-Specific Prevalence of Interstitial Lung Disease (ILD) in the United States
5.1.4. Subtype-Specific Prevalence of Interstitial Lung Disease (ILD) in the US
5.1.5. Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Prevalent Cases of Interstitial Lung Disease (ILD) in Germany
5.2.1.3. Type-Specific Prevalence of Interstitial Lung Disease (ILD) in Germany
5.2.1.4. Subtype-Specific Prevalence of Interstitial Lung Disease (ILD) in Germany
5.2.1.5. Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Prevalent Cases of Interstitial Lung Disease (ILD) in France
5.2.2.3. Type-Specific Prevalence of Interstitial Lung Disease (ILD) in France
5.2.2.4. Subtype-Specific Prevalence of Interstitial Lung Disease (ILD) in France
5.2.2.5. Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Prevalent Cases of Interstitial Lung Disease (ILD) in Italy
5.2.3.3. Type-Specific Prevalence of Interstitial Lung Disease (ILD) in Italy
5.2.3.4. Subtype-Specific Prevalence of Interstitial Lung Disease (ILD) in Italy
5.2.3.5. Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Prevalent Cases of Interstitial Lung Disease (ILD) in Spain
5.2.4.3. Type-Specific Prevalence of Interstitial Lung Disease (ILD) in Spain
5.2.4.4. Subtype-Specific Prevalence of Interstitial Lung Disease (ILD) in Spain
5.2.4.5. Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Prevalent Cases of Interstitial Lung Disease (ILD) in the United Kingdom
5.2.5.3. Type-Specific Prevalence of Interstitial Lung Disease (ILD) in the United Kingdom
5.2.5.4. Subtype-Specific Prevalence of Interstitial Lung Disease (ILD) in the United Kingdom
5.2.5.5. Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Prevalent Cases of Interstitial Lung Disease (ILD) in Japan
5.3.3. Type-Specific Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Japan
5.3.4. Subtype-Specific Prevalence of Interstitial Lung Disease (ILD) in Japan
5.3.5. Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Japan

6. Treatment and Management of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
6.1. Treatment Guidelines for Progressive-Fibrosing Lung Disease (PD-ILD)
6.1.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis
6.1.2. EULAR Recommendations for the Treatment of Systemic Sclerosis (SSc-ILD)
6.1.3. German Guideline for Idiopathic Pulmonary Fibrosis (IPF-ILD)
6.1.4. France Practical Guidelines for the Diagnosis and Management of Idiopathic Pulmonary Fibrosis (IPF-ILD)

7. Unmet Needs

8. Emerging Drugs
8.1. Nintedanib: Boehringer Ingelheim
8.1.1. Product Description
8.1.2. Other Developmental Activities
8.1.3. Clinical Development
8.1.4. Clinical Trials Information
8.1.5. Safety and Efficacy
8.1.6. Product Profile
8.2. Pirfenidone: Roche
8.2.1. Product Description
8.2.2. Other Developmental Activities:
8.2.3. Clinical Development
8.2.4. Clinical Trials Information
8.2.5. Safety and Efficacy
8.2.6. Product Profile

9. Progressive-fibrosing interstitial lung disease (PF-ILD): 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Progressive-fibrosing interstitial lung disease (PF-ILD) in the 7MM
9.3. Market Size of Progressive-fibrosing interstitial lung disease (PF-ILD) by Therapies in the 7MM

10. Market Outlook: 7MM
10.1. United States Market Size
10.1.1. The total Market size of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
10.1.2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market by Current Treatment and Emerging Therapies
10.2. EU5
10.2.1. Germany
10.2.1.1. Total Market size of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
10.2.1.2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market by Current Treatment and Emerging Therapies
10.2.2. France
10.2.2.1. Total Market size of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
10.2.2.2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market by Current Treatment & Emerging Therapies
10.2.3. Italy
10.2.3.1. Total Market size of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
10.2.3.2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market by Current Treatment & Emerging Therapies
10.2.4. Spain
10.2.4.1. Total Market size of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
10.2.4.2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market by Current Treatment and Emerging Therapies
10.2.5. United Kingdom
10.2.5.1. Total Market size of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
10.2.5.2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market by Current Treatment and Emerging Therapies
10.3. Japan
10.3.1. Total Market size of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
10.3.2. Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Market by Current Treatment & Emerging Therapies

11. Market Drivers

12. Market Barriers

13. SWOT Analysis

14. Appendix
14.1. Report Methodology

15. Researcher Capabilities

16. Disclaimer

17. About the Publisher

List of Tables:
Table 1 Total Prevalent Patient Population of Interstitial Lung Disease (ILD) in 7MM (2017-2028)
Table 2 Subtype-Specific Prevalence of ILD in the United States (2017-2028)
Table 3 Total Prevalent Patient Population of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM (2017-2028)
Table 4 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) by subtypes in the 7MM (2017-2028)
Table 5 Total Prevalent Population of ILD in the United States (2017-2028)
Table 6 Type-Specific Prevalence of ILD in the United States (2017-2028)
Table 7 Subtype-Specific Prevalence of ILD in the United States (2017-2028)
Table 8 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the United States (2017-2028)
Table 9 Total Prevalent Population of ILD in Germany (2017-2028)
Table 10 Type-Specific Prevalence of ILD in Germany (2017-2028)
Table 11 Subtype-Specific Prevalence of ILD in Germany (2017-2028)
Table 12 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Germany (2017-2028)
Table 13 Total Prevalent Population of ILD in France (2017-2028)
Table 14 Type-Specific Prevalence of ILD in France (2017-2028)
Table 15 Subtype-Specific Prevalence of ILD in France (2017-2028)
Table 16 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in France (2017-2028)
Table 17 Total Prevalent Population of ILD in Italy (2017-2028)
Table 18 Type-Specific Prevalence of ILD in Italy (2017-2028)
Table 19 Subtype-Specific Prevalence of ILD in Italy (2017-2028)
Table 20 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Italy (2017-2028)
Table 21 Total Prevalent Population of ILD in Spain (2017-2028)
Table 22 Type-Specific Prevalence of ILD in Spain (2017-2028)
Table 23 Subtype-Specific Prevalence of ILD in Spain (2017-2028)
Table 24 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Spain (2017-2028)
Table 25 Total Prevalent Population of ILD in the United Kingdom (2017-2028)
Table 26 Type-Specific Prevalence of ILD in the UK (2017-2028)
Table 27 Subtype-Specific Prevalence of ILD in the UK (2017-2028)
Table 28 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the United Kingdom (2017-2028)
Table 29 Total Prevalent Population of ILD in Japan (2017-2028)
Table 30 Type-Specific Prevalence of ILD in Japan (2017-2028)
Table 31 Subtype-Specific Prevalence of ILD in Japan (2017-2028)
Table 32 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Japan (2017-2028)
Table 33 Nintedanib, Clinical Trial Description, 2019
Table 34 Pirfenidone , Clinical Trial Description, 2019
Table 35 Market size of PF-ILD by Region in USD Million (2017–2028)
Table 36 7MM Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Table 37 United States Market Size of PF-ILD in USD Million (2017-2028)
Table 38 The US Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Table 39 Germany Market Size of PF-ILD in USD Million (2017-2028)
Table 40 Germany Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Table 41 France Market Size of PF-ILD in USD Million (2017-2028)
Table 42 France Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Table 43 Italy Market Size of PF-ILD in USD Million (2017-2028)
Table 44 Italy Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Table 45 Spain Market Size of PF-ILD in USD Million (2017-2028)
Table 46 Spain Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Table 47 United Kingdom Market Size of PF-ILD in USD Million (2017-2028)
Table 48 The UK Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Table 49 Japan Market Size of PF-ILD in USD Million (2017-2028)
Table 50 Japan Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)

List of Figures:
Figure 1 ILDs with overlapping area shows the probability of having a progressive-fibrosing phenotype
Figure 2 Known and Unknowns of PF-ILDs
Figure 3 Types of ILD most likely to have a progressive-fibrosing phenotype
Figure 4 Fibrosis of the alveolus wall
Figure 5 Types of Connective tissue disease-associated interstitial lung disease (CTD-ILD)
Figure 6 Concepts in the pathogenesis of RA-ILD
Figure 7 Mechanisms involved in the pathogenesis and progression of fibrosing interstitial lung diseases
Figure 8 Diagnosis of ILDs that may present a progressive phenotype
Figure 9 Total Prevalent Patient Population of Interstitial Lung Disease (ILD) in the 7MM (2017-2028)
Figure 10 Subtype-Specific Prevalence of ILD in the United States (2017-2028)
Figure 11 Total Prevalent Patient Population of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM (2017-2028)
Figure 12 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) by subtypes in the 7MM (2017-2028)
Figure 13 Total Prevalent Cases of ILD in the United States (2017-2028)
Figure 14 Type-Specific Prevalence of ILD in the United States (2017-2028)
Figure 15 Subtype-Specific Prevalence of ILD in the United States (2017-2028)
Figure 16 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the United States (2017-2028)
Figure 17 Total Prevalent Cases of ILD in Germany (2017-2028)
Figure 18 Type-Specific Prevalence of ILD in Germany (2017-2028)
Figure 19 Subtype-Specific Prevalence of ILD in Germany (2017-2028)
Figure 20 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Germany (2017-2028)
Figure 21 Total Prevalent Cases of ILD in France (2017-2028)
Figure 22 Type-Specific Prevalence of ILD in France (2017-2028)
Figure 23 Subtype-Specific Prevalence of ILD in France (2017-2028)
Figure 24 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in France(2017-2028)
Figure 25 Total Prevalent Cases of ILD in Italy (2017-2028)
Figure 26 Type-Specific Prevalence of ILD in Italy (2017-2028)
Figure 27 Subtype-Specific Prevalence of ILD in Italy (2017-2028)
Figure 28 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Italy (2017-2028)
Figure 29 Total Prevalent Cases of ILD in Spain (2017-2028)
Figure 30 Type-Specific Prevalence of ILD in Spain (2017-2028)
Figure 31 Subtype-Specific Prevalence of ILD in Spain (2017-2028)
Figure 32 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Spain (2017-2028)
Figure 33 Total Prevalent Cases of ILD in the United Kingdom (2017-2028)
Figure 34 Type-Specific Prevalence of ILD in the United Kingdom (2017-2028)
Figure 35 Subtype-Specific Prevalence of ILD in the United Kingdom (2017-2028)
Figure 36 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in the United Kingdom (2017-2028)
Figure 37 Total Prevalent Cases of ILD in Japan (2017-2028)
Figure 38 Type-Specific Prevalence of ILD in Japan (2017-2028)
Figure 39 Subtype-Specific Prevalence of ILD in Japan (2017-2028)
Figure 40 Prevalence of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) in Japan (2017-2028)
Figure 41 Current understanding of the mode of action of nintedanib in fibrotic lung diseases
Figure 42 Unmet Needs
Figure 43 Mechanism of action of Nintedanib
Figure 44 Regulatory Milestones of Nintedanib
Figure 45 Clinical Development of Nintedanib
Figure 46 Market size of PF-ILD by Region in USD Million (2017–2028)
Figure 47 Market Size of PF-ILD by Therapies in the 7MM, in USD Million (2017–2028)
Figure 48 United States Market Size of PF-ILD in USD Million (2017-2028)
Figure 49 The US Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Figure 50 Germany Market Size of PF-ILD in USD Million (2017-2028)
Figure 51 Germany Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Figure 52 France Market Size of PF-ILD in USD Million (2017-2028)
Figure 53 France Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Figure 54 Italy Market Size of PF-ILD in USD Million (2017-2028)
Figure 55 Italy Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Figure 56 Spain Market Size of PF-ILD in USD Million (2017-2028)
Figure 57 Spain Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Figure 58 United Kingdom Market Size of PF-ILD in USD Million (2017-2028)
Figure 59 The UK Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Figure 60 Japan Market Size of PF-ILD in USD Million (2017-2028)
Figure 61 Japan Market Size of PF-ILD by Current Treatment and Emerging Therapies in USD Million (2017-2028)
Figure 62 Market Drivers
Figure 63 Market Barriers
Figure 64 Ofev for IPF/SSc-ILD/PF-ILD - SWOT analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Boehringer Ingelheim
  • Roche
Note: Product cover images may vary from those shown
Adroll
adroll